Serhii Shevnia

A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC

I. Bondarenko, M. Reck, N. Kovalenko, 2019, Annals of Oncology.